| Malignant
Brain Tumors & Neuro-Oncology
Resources
MGH BTC
| Referrals
| BTC Guestbook
| Links | or see Benign
Brain Tumors
|
MGH
Brain Tumor Center
Adult Brain and Spine Tumors
Information on the MGH
Brain Tumor Center
Adult Brain and Spine Tumors
- Pediatric
Brain, Spine, and Peripheral Neuroblast Tumors
- Neuropathology
and the Neuropathology Consultation
Service
- Proton
Beam Stereotactic Radiosurgery Homepage
- MGH Neuro-oncology
Information Resources (general information about brain,
spine, and peripheral nerve tumors)
- Benign
brain and spine tumors such as meningioma, epidermoid,
dermoid, hemangioblastoma, colloid cyst, subependymal giant
cell astrocytoma, pleomorphic xanthoastrocytoma, and craniopharyngioma.
- Acoustic
neuroma and other cerebellopontineangle (cpa) and skull
base tumors
- Pituitary
tumor (adenoma, carcinoma) information
- Neurofibromatosis
(type I, Von Recklinghausen's disease) information
- Tuberous
sclerosis resources
- Von
Hippel-Lindau disease resources
- Links to other
Neuro-oncology information and support resources
- Return to the MGH
Neurosurgery Homepage
|
![[Neurooncology Resources]](images/BTChome2.JPG) |
Malignant Tumors: Information regarding the treatment of
malignant brain, spine, and peripheral nerve tumors at Massachusetts
General Hospital and links to other nervous system tumor resources. |
Therapy for primary
and metastatic tumors of the brain, spine, and of peripheral nerves
is determined on an individual basis by informed agreement of patient,
family, and the members of the Brain Tumor Center.
The MGH BTC medical staff
specializes in using modern neuroimaging techniques such as positron
emission tomography (PET scanning) and functional magnetic resonance
imaging (fMRI) to ensure the most accurate diagnostic biopsies and
maximal resection of benign and malignant primary and metastatic
tumors of brain, spine, and peripheral nerves. Both PET and many
advaneces in MRI were initiated at MGH and are under current development
here. In addition, these techniques are supplemented by intraoperative
functional mapping and physiologic monitoring when these techniques
are appropriate to ensure maximal tumor removal. Active surgical
research protocols include interstitial photon irradiation technology
developed as MGH and clinical trials of the implantation of chemotherapy
releasing biopolymers at the time of surgical tumor resection.
Therapy
for primary and metastatic tumors of the brain, spine, and of peripheral
nerves is determined on an individual basis by informed agreement
of patient, family, and the members of the Brain Tumor Center.
The MGH BTC medical staff
specializes in using modern neuroimaging techniques such as positron
emission tomography (PET scanning) and functional magnetic resonance
imaging (fMRI) to ensure the most accurate diagnostic biopsies and
maximal resection of benign and malignant primary and metastatic
tumors of brain, spine, and peripheral nerves. Both PET and many
advaneces in MRI were initiated at MGH and are under current development
here. In addition, these techniques are supplemented by intraoperative
functional mapping and physiologic monitoring when these techniques
are appropriate to ensure maximal tumor removal. Active surgical
research protocols include interstitial photon irradiation technology
developed as MGH and clinical trials of the implantation of chemotherapy
releasing biopolymers at the time of surgical tumor resection.
Active
state of the art therapies are available for range of adult
brain and spine tumor histologies.
Pediatric Brain, Spine,
and Peripheral Neuroblast Tumors
Pediatric brain tumors
are treated by a multidisciplinary group including pediatric oncologists,
pediatric neurologists, radiation oncologists, and pediatric
neurosurgeons . See the MGH Pediatric
Neurosurgery Homepage for a listing of MGH neurosurgeons with
special expertise in the treatment of pediatric brain tumors. Proton
beam stereotactic radiosurgery is also available for the treatment
of pediatric brain, and spine tumors.
Appointments may be coordinated
through the MGH Pediatric Neurology Service:
Elizabeth Dooling, M.D.
Director, Pediatric Neurology
Vincent-Burnham Kennedy-7
Massachusetts General Hospital
Boston, MA 02114
phone: (617) 726-3877
Investigational treatment
protocols for children including chemotherapy are coordinated through
the pediatric oncology service.
For more information or
to make an appointment contact MGH Pediatric Oncology:
David Ebb, M.D.
Director, Pediatric Oncology
Blake Building, Second Floor
Massachusetts General Hospital
Boston, MA 02114
phone: (617) 726-2737
Protocols therapy is currently
available for the following tumor types. Data collection for the
majority of these protocols is coordinated by the pediatric oncology
group. Non-protocol therapies are available for tumors of any type.
- Low-grade astrocytoma
- primary: POG Intergroup protocol
- recurrent: idarubicin-based
therapy and topotecan -based therapy)
- Optic pathway tumors
- Ependymomas
- Brain stem gliomas
- topotecan -based therapy
- taxol-based therapy
- Craniopharyngioma (see
above )
- Supratentorial neoplasms (1. malignant
gliomas: anaplastic astrocytoma, glioblastoma multiforme, malignant
gliosarcoma, and malignant oligodendrogiomas; malignant small
cell neoplasms with glial differentiation are also eligible.
2. Poorly-differentiated embryonal cell tumors (PDETs): undifferentiatied
malignant small cell neoplasm, as well as those with pineal
(pineoblastomas), ependymal (ependymoblastomas), or neuronal
(primary cerebral neuroblastoma) differentiation, including
cases diagosed as PNET.)
- Medulloblastoma (infratentorial
PNET)
- POG low stage protocol
- POG high stage protocol
- recurrent: taxol
- subquent recurrence: POG salvage
protocol
Special protocols are
also available for children under 3 years of age with tumors of
various histologies.
MGH
Neuropathology and the Neuropathology Consultation Service Patholgic
consultations regarding central and peripheral nervous system tumors
are available from the Neuropathology Service. Prior to sending
the original pathology report as well as slides (and tissue blocks
if available) either of the following should be contacted:
E. Tessa Hedley-Whyte, M.D.
Department of Pathology (Neuropathology)
Warren-3
Massachusetts General Hospital
Boton, MA 02114
phone (617) 726-5156
or
David
N. Louis, M.D.
phone (617) 726-5510
fax (617) 726-5079
|